The resulting drug, Rybelsus, was approved by the FDA in 2019
Li Q, Jia M, Yan Z, et al
Ileus: This is a condition where the normal wave-like contractions of the intestines (peristalsis) stop, preventing food and waste from moving through the digestive tract
That comparison is from the studied FDA-approved products under trial conditions - it's relevant context for understanding why tirzepatide's higher efficacy average might justify its slightly higher price point, but it doesn't predict the gap in any individual patient's results
In these cases, the concern may not be loose skin alone
Understanding which foods to avoid and what to eat on GLP-1 therapy makes a meaningful difference in both tolerability and results